(MedPage Today) — The FDA approved enlicitide (Lipfendra) as the first oral PCSK9 inhibitor for lowering cholesterol. Enlicitide is now approved as an adjunct to diet and exercise to reduce LDL cholesterol in adults with high cholesterol or heterozygous…
Source: MedPage Today — Headlines
